400 Shares in Eli Lilly and Company (NYSE:LLY) Acquired by Iyo Bank Ltd.

Iyo Bank Ltd. acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 400 shares of the company’s stock, valued at approximately $311,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Sivia Capital Partners LLC grew its stake in Eli Lilly and Company by 5.0% in the 1st quarter. Sivia Capital Partners LLC now owns 1,868 shares of the company’s stock valued at $1,454,000 after buying an additional 89 shares in the last quarter. Monument Capital Management grew its position in shares of Eli Lilly and Company by 1.3% in the first quarter. Monument Capital Management now owns 2,916 shares of the company’s stock valued at $2,268,000 after purchasing an additional 38 shares in the last quarter. Azzad Asset Management Inc. ADV raised its stake in shares of Eli Lilly and Company by 2.5% during the 1st quarter. Azzad Asset Management Inc. ADV now owns 1,814 shares of the company’s stock valued at $1,411,000 after purchasing an additional 45 shares during the period. Saxon Interests Inc. purchased a new stake in Eli Lilly and Company during the 1st quarter worth about $261,000. Finally, Naviter Wealth LLC boosted its stake in Eli Lilly and Company by 18.3% in the 1st quarter. Naviter Wealth LLC now owns 4,318 shares of the company’s stock worth $3,359,000 after purchasing an additional 668 shares during the period. 82.53% of the stock is owned by institutional investors.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 8,848 shares of the company’s stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $915.31, for a total transaction of $8,098,662.88. Following the completion of the transaction, the insider now owns 97,299,772 shares of the company’s stock, valued at approximately $89,059,454,309.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, EVP Johna Norton sold 7,056 shares of Eli Lilly and Company stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total value of $5,781,545.28. Following the sale, the executive vice president now owns 25,428 shares in the company, valued at $20,835,194.64. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 8,848 shares of the company’s stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $915.31, for a total transaction of $8,098,662.88. Following the completion of the transaction, the insider now owns 97,299,772 shares of the company’s stock, valued at $89,059,454,309.32. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 858,742 shares of company stock worth $735,573,781. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Down 0.9 %

NYSE LLY opened at $898.10 on Thursday. The firm has a market cap of $853.56 billion, a PE ratio of 132.27, a price-to-earnings-growth ratio of 1.98 and a beta of 0.41. Eli Lilly and Company has a 1-year low of $434.34 and a 1-year high of $918.50. The stock has a 50-day moving average of $821.29 and a 200-day moving average of $745.62. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. During the same period in the previous year, the firm earned $1.62 EPS. The business’s quarterly revenue was up 26.0% on a year-over-year basis. As a group, sell-side analysts forecast that Eli Lilly and Company will post 13.76 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 0.58%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is 76.58%.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on LLY shares. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Citigroup boosted their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. BMO Capital Markets reaffirmed an “outperform” rating and issued a $1,001.00 price target on shares of Eli Lilly and Company in a report on Wednesday. Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a research note on Monday. Finally, Jefferies Financial Group upped their target price on Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research note on Monday, June 24th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $812.72.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.